Article

Cerebral organoids expressing mutant actin genes reveal cellular mechanism underlying microcephalic cortical malformation

Indra Niehaus[1], Michaela Wilsch-Bräuninger[2], Felipe Mora-Bermúdez[2], Mihaela Bobic-Rasonja[3], Velena Radosevic[4], Marija Milkovic-Perisa[5], Pauline Wimberger[6], Mariasavina Severino[7], Alexandra Haase[8], Ulrich Martin[8], Karolina Kuenzel[9], Kaomei Guan[9], Katrin Neumann[10], Noreen Walker[2], Evelin Schröck[1], Natasa Jovanov-Milosevic[3§], Wieland B. Huttner[2*], Nataliya Di Donato[1*], Michael Heide[2,11*]

[1]Institute for Clinical Genetics, Technische Universität Dresden, and National Cancer Center (NCT) Dresden, 01307 Dresden, Germany.

[2]Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.

[3]Croatian Institute of Brain Research and Department of Biology, School of Medicine, University of Zagreb, Salata 12, Zagreb, Croatia

[4]Department of Obstetrics and Gynecology, University Hospital Centre, Petrova 13, Zagreb, Croatia

[5]Department of Pathology and Cytology, School of Medicine, University of Zagreb and University Hospital Centre, Kispaticeva 14, Zagreb, Croatia

[6]Department of Gynecology and Obstetrics, Technische Universität Dresden, and National Cancer Center (NCT) Dresden, 01307 Dresden, Germany.

[7]Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.

[8]Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiac, Thoracic, Transplantation, and Vascular Surgery, REBIRTH – Research Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany.

[9]Institute of Pharmacology and Toxicology, Technische Universität Dresden, 01307 Dresden, Germany

[10]Center for Regenerative Therapies Dresden (CRTD, Stem Cell Engineering Facility), Technische Universität Dresden, 01307 Dresden, Germany.

[11]German Primate Center, Leibniz Institute for Primate Research, Kellnerweg 4, 37077 Göttingen, Germany

[§] Correspondence for paraffin-embedded fetal human brain tissue

* Corresponding authors with equal contributions

Abstract

Pathogenic *ACTB* and *ACTG1* gene variants, encoding the actin isoforms βCYA and γCYA, respectively, are frequently associated with the Baraitser-Winter-CerebroFrontoFacial syndrome (BWCFF-S) that includes malformations of cortical development. Here we explore whether cerebral organoids grown from BWCFF-S patient-derived induced pluripotent stem cells can provide insight into the pathogenesis underlying the cortical malformations of these patients. Cerebral organoids expressing either an *ACTB* or an *ACTG1* gene variant, each with a point mutation resulting in a single amino acid substitution, are reduced in size, showing smaller ventricle-like structures with a thinner ventricular zone (VZ). This decrease in VZ-progenitors is associated with a striking change in the orientation of their cleavage plane from predominantly vertical (control) to predominantly horizontal (BWCFF-S), which is incompatible with increasing VZ-progenitor abundance. The underlying cause appears to be an altered subcellular tubulin localization due to the actin mutations that affects mitotic spindle positioning of VZ-progenitors in BWCFF-S.

Actin is an abundantly expressed protein found in virtually all eukaryotic cells, with multiple functions in critical cellular processes[1,2]. While it is often regarded as just “actin”, human actin consists of 6 actin isoforms encoded by 6 genes with tissue-specific expression, *ACTA1* ($\alpha_{skeletal}$-actin), *ACTA2* (α_{smooth}-actin), *ACTB* ($\beta_{cytoskeletal}$-actin, βCYA), *ACTC1* ($\alpha_{cardiac}$-actin), *ACTG1* ($\gamma_{cytoskeletal}$-actin, γCYA) and *ACTG2* (γ_{smooth}-actin)[3].

Pathogenic variants in the genes encoding for the muscle actin isoforms, *ACTA1, ACTA2, ACTC1* and *ACTG2* result in different forms of either skeletal and visceral myopathies or vasculopathies[4]. Pathogenic variants in the genes *ACTB* and *ACTG1*, encoding the ubiquitously expressed βCYA and γCYA, are associated with the systemic Mendelian disorder called Baraitser-Winter-CerebroFrontoFacial syndrome (BWCFF-S)[5,6]. BWCFF-S is characterized by a wide spectrum of variable congenital anomalies, with the central nervous system frequently being affected. Nearly all patients show intellectual impairment[6-8], and almost half of the BWCFF-S patients exhibit cortical malformations, with microcephaly and lissencephaly as the most common forms[9,39]. Currently, the available neuropathological data of BWCFF-S patients are limited to three reports, which however lack specific data on the cytoarchitecture of the BWCFF-S neocortex[10-12]. Moreover, the developmental mechanisms underlying the BWCFF-S–associated cortical malformations are unknown.

BWCFF-S disease models could provide functional insights into the role of the above-mentioned two CYA isoforms during pathophysiological neocortex development. However, the available mouse *Actb* knock-out (KO) and *Actg1* KO models[13,14] do not faithfully reproduce the BWCFF-S-associated cortical malformations, which – besides the difference between an actin KO and expression of a mutant actin – is not surprising in light of the differences in cortical development between mouse and human. Therefore, other models of human corticogenesis are needed that better recapitulate human physiological and pathophysiological neocortex development. Recently, a promising model for this emerged in the form of brain organoids[15,16]. Brain organoids are organized three-dimensional cell aggregates generated from pluripotent

stem cells that recapitulate many features of the developing brain (including the neocortex)[17-22]. Moreover, several studies showed the usefulness of brain organoids in the modelling and functional characterization of cortical malformations[16,23-28]. Human brain organoids carrying pathogenic variants of the actin genes associated with BWCFF-S would have the potential to overcome the limitations of rodent models and could provide insight into the underlying mechanism of the formation of BWCFF-S-associated cortical malformations.

In this study, we generated patient-derived induced pluripotent stem cells (iPSCs) carrying a pathogenic gene variant of either *ACTB* or *ACTG1*, and used these to grow human cerebral organoids, a specific type of brain organoids, in order to model the BWCFF-S–associated microcephaly. For this purpose, we first confirmed that human cerebral organoids in essence recapitulate the widespread distribution of βCYA and γCYA in fetal human cerebral cortex and can be used as a model for actinopathies, such as BWCFF-S. We then compared cerebral organoids derived from two different healthy control iPSC lines to those derived from the two BWCFF-S patient iPSC lines. We found that BWCFF-S-derived cerebral organoids exhibit a smaller size and an abnormal VZ morphology. Moreover, mitotic apical progenitors (APs; for the terminology of APs vs. VZ progenitors, see Methods) in the VZ shifted the orientation of their cleavage plane from predominantly vertical (control organoids) to predominantly horizontal (BWCFF-S organoids), which prevents the symmetric proliferative divisions of APs that are required to increase their abundance. Finally, as cleavage plane orientation depends on the orientation of the mitotic spindle, which involves microtubules, we analyzed microtubule organization and found a striking concentration of both alpha- and beta-tubulin at the apical cell cortex of APs in BWCFF-S organoids. Together, our data suggests that the underlying mechanism of BWCFF-S-associated microcephaly is a predominantly horizontal cleavage plane orientation of mitotic APs likely caused by alterations of the microtubule organization at the apical cell cortex.

Results

Cortical malformations in BWCFF-S patients

To broaden our view of the cortical malformations found in BWCFF-S patients, we reviewed the literature on the neurological manifestations in patients carrying pathogenic variants (or likely pathogenic variants) of *ACTB* and *ACTG1* genes[5,6,9,29-32]. We combined this literature review with an analysis of brain imaging data of 29 not previously reported patients carrying pathogenic variants of *ACTB* (20 patients) and *ACTG1* (9 patients) (data not shown). We confirmed the previous observation[6] that malformations of cortical development were present in almost 70% of BWCFF-S patients. Fig. 1 shows representative brain MRI images illustrating malformations typically associated with the BWCFF-S in comparison to the images of a healthy individual (panels A-C). Two of the patients (Fig. 1, D-F and J-L) each carry a point mutation in *ACTB* which results in a single amino acid substitution, of which the BWCFF-S patient with the actin variant NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile (Fig. 1D-F) will serve as source for one set of the cerebral organoids studied here (see below). The other two patients (Fig. 1, G-I and M-O) each carry a point mutation in *ACTG1* which also results in a single amino acid substitution, of which the BWCFF-S patient with the actin variant NM_001614.5(*ACTG1*):c.608C>T p.Thr203Met (Fig. 1G-I) will serve as source for another set of the cerebral organoids studied here (see below).

The patient with the *ACTB* variant p.Thr120Ille was reported previously[29] and had microcephaly with a head circumference of –2.5 SD and severe intellectual disability with an IQ <40. Briefly, the brain malformations in this patient included frontal predominant pachygyria (Fig. 1E) and periventricular nodular heterotopia located bilaterally in the occipital horns of the lateral ventricles (Fig. 1F). The patient carrying the variant *ACTG1* p.Thr203Met in was non-ambulant, showed severe microcephaly of –5.2 SD and had no speech development with an IQ <40. Brain MRI demonstrated frontotemporal pachygyria (Fig. 1H,I) accompanied by agenesis of the corpus callosum and cerebellar hypoplasia (Fig. 1G). Fig. 1J-L shows a brain

MRI from a second patient carrying a pathogenic *ACTB* variant, NM_001101.5(*ACTB*):c.571A>G, p.Lys191Glu. This patient had microcephaly of –3.5 SD, and the brain MRI showed bilateral anterior-predominant pachygyria, with very prominent perivascular spaces (Fig. 1K). A second patient carrying a pathogenic *ACTG1* variant is presented in Fig. 1M-O. This patient was previously reported[30] and carries the mutation NM_001614.5(*ACTG1*):c.767G>A, p.Arg256Gln, located at a mutational hotspot. Briefly, the brain MRI images of this patient demonstrated partial agenesis of the corpus callosum (Fig. 1M) and a very specific pattern of cortical malformations consistent with frontal predominant pachygyria associated with a thin posterior band heterotopia (Fig. 1N,O).

Widespread distribution of βCYA and γCYA in human cerebral organoids, similar to fetal human neocortex

Prior to generating cerebral organoids from BWCFF-S patient-derived iPSCs, we first determined whether the expression patterns of βCYA and γCYA in human cerebral organoids generated from control iPSCs would be similar, in principle, to those in fetal human neocortex, which we considered to be a prerequisite for using cerebral organoids as a model for BWCFF-S. As shown by immunohistochemistry in Suppl. Figs. 1 and 2 for 12 and 16 weeks post conception (wpc) fetal human neocortex tissue, respectively, both βCYA and γCYA showed a widespread distribution across the developing cortical wall, from the VZ all the way to the marginal zone, with the peak of immunoreactivity in the apical-most region of the VZ which is known to harbor the apical adherens junction (AJ) belt.

To investigate whether cerebral organoids show similar widespread βCYA and γCYA expression patterns as observed in fetal human neocortex tissue, we generated cerebral organoids from two human control iPSC lines, SC102A and CRTDi011-A. Immunohistochemistry of these organoids at day 30 of culture revealed an, in principle, similar widespread distribution of both βCYA and γCYA across the wall of the ventricle-like structures, from the ventricular surface to the outer surface (Suppl. Fig. 3, c1 and c2). Again, within the

VZ of the organoids, βCYA and γCYA immunoreactivity was concentrated towards the apical surface.

Given this widespread distribution of both βCYA and γCYA in the control cerebral organoids, we checked the expression of canonical markers in these organoids under the present conditions, again using immunohistochemistry. Consistent with previous reports[15,16,33], the control cerebral organoids after 30 days in culture were found to express markers of proliferating progenitors (SOX2), neurogenic basal progenitors (TBR2), and newborn neurons (Tuj1) including deep-layer neurons (CTIP2) (Suppl. Fig. 4, Suppl. Fig. 5, c1 and c2). Immunostaining for nestin revealed a radially organized VZ, with densely packed nuclei as seen by DAPI staining or SOX2 immunostaining (Suppl. Fig. 4 c1 and c2).

Generation of cerebral organoids from BWCFF-S patient-derived iPSCs

Next, we sought to model BWCFF-S in cerebral organoids. To this end, we collected fibroblasts from two BWCFF-S patients, carrying either the actin variant NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile (Fig. 1D-F) or the actin variant NM_001614.5(*ACTG1*):c.608C>T p.Thr203Met (Fig. 1G-I), and reprogrammed them into iPSCs. The two sets of iPSCs exhibited normal karyotype and expressed typical pluripotency markers (data not shown). We generated cerebral organoids from two clones of each patient-derived iPSC line.

Next, we explored whether cerebral organoids generated from the BWCFF-S patient-derived iPSCs showed a similar widespread βCYA and γCYA distribution and canonical marker expression as the control organoids and hence could be suitable models to study the disrupted early cortical development characteristic of such patients. Indeed, immunohistochemistry at day 30 of culture revealed that both types of organoids, expressing either the *ACTB* variant or the *ACTG1* variant, showed a similar widespread distribution of both βCYA and γCYA across the various zones of the wall of the ventricle-like structures (Suppl. Fig. 3). For the *ACTG1* variant-expressing organoids, a concentration of βCYA and γCYA immunoreactivity at the

apical surface of the VZ could be observed. Like control organoids, both the *ACTB* or *ACTG1* variant-expressing organoids showed SOX2, TBR2, Tuj1 (Suppl. Fig. 5), CTIP2 and nestin (Suppl. Fig. 4) immunoreactivity in the typical locations. We conclude that the cerebral organoids generated from the BWCFF-S patient-derived iPSCs can be suitable models to study the microcephaly observed in these patients.

BWCFF-S cerebral organoids are significantly reduced in size

In the above-described immunostainings, we had noticed that the ventricle-like structures in the BWCFF-S organoids appeared to be smaller than those in the control organoids. We therefore decided to quantitatively compare various size parameters of the BWCFF-S organoids vs. control organoids. As the first step in the analyses, we quantified the entire size of the cerebral organoids. At 30 days of cerebral organoid culture, the two types of BWCFF-S organoids were significantly smaller compared to control organoids (Fig. 2A,C). Moreover, at 50 days of organoid culture, a similar size difference was observed (Fig. 2B,D), suggesting that both the control and the two types of BWCFF-S cerebral organoids were growing at similar speed between day 30 and day 50 of culture. These data are in line with the microcephaly observed in the two patients and in at least half of the whole BWCFF-S cohort[6], and indicate that BWCFF-S cerebral organoids can recapitulate features of the patients' phenotype.

BWCFF-S cerebral organoids exhibit a massive reduction in VZ progenitors

Further analyses revealed that the size of the ventricle-like structures and the morphology of the VZ in the two types of BWCFF-S organoids differed significantly from the controls (Fig. 3). To better characterize this abnormal morphology, we quantified different parameters of the VZ in the control and the BWCFF-S cerebral organoids at 30 days of organoid culture, as already at this time point the size difference was obvious. For this purpose, we used DAPI-stained control and BWCFF-S cerebral organoids and first determined the radial thickness of the VZ (Fig. 3A). We found a significantly reduced VZ radial thickness for the two types of BWCFF-S organoids compared to control organoids (Fig. 3B), indicating a thinner VZ likely caused by a

reduced cell number. We next quantified the perimeter of the VZ, which also was smaller in the BWCFF-S VZ compared to the VZ of control organoids (Fig. 3C). Moreover, to corroborate the reduction in VZ size in the two types of BWCFF-S organoids compared to control, we measured the total area occupied by the VZ and found a significant reduction of VZ area in the two types of BWCFF-S cerebral organoids compared to control (Fig. 3D).

Despite the reduction in these three VZ parameters, the density of cell nuclei in the VZ was similar for the two types of BWCFF-S organoids as compared to control organoids (Fig. 3E,F). Considering these four VZ parameters together, these data strongly suggested that the reduction in the former three VZ parameters (Fig. 3A-D) of the BCWFF-S organoids was likely caused by a decrease in VZ progenitors. Indeed, quantification of the DAPI-stained nuclei revealed a substantial decrease of the number of VZ progenitors per ventricle-like structure in the BWCFF-S organoids as compared to control organoids (Fig. 3G). Such a decrease can have various causes, including diminished proliferation of VZ progenitors or their increased apoptotic cell death. However, caspase 3 staining showed that apoptotic cells were rare in both BWCFF-S and control organoids (Suppl. Fig. 6).

Quantification of Ki-67– and PH3–positive cells in the VZ revealed no significant differences in these markers of cycling cells between the BWCFF-S and control organoids (Suppl. Fig. 7). However, these cycling cell markers do not distinguish between the various modes of cell division in the VZ, that with regard to the two classes of progenitors found in the VZ (see terminology in Methods) apply only to APs; these modes of AP division may be either (i) symmetric–proliferative (1 AP –> 2 APs), resulting in an increase in AP and hence VZ progenitor number; (ii) asymmetric–self-renewing (1 AP –> 1 AP + 1 cell that leaves the VZ, typically a basal progenitor), resulting in the maintenance of AP number but a transient increase in VZ progenitor number; or (iii) self-consuming (1 AP –> 2 cells that leave the VZ), resulting in a decrease of AP number but a transient increase in VZ progenitor number.

Mitotic APs in BWCFF-S organoids show horizontal rather than vertical cleavage planes

We therefore explored whether the mode of AP division was altered in the BWCFF-S organoids as compared to control organoids. Clues in this regard can be obtained from an analysis of the orientation of the cleavage plane of mitotic APs. The cleavage plane orientation of mitotic APs normally is predominantly vertical (i.e. parallel to the apical-basal axis of the cell); such a cleavage plane orientation is required for symmetric–proliferative divisions of APs, but is also compatible with asymmetric–self-renewing divisions of these progenitors. In contrast, a horizontal cleavage plane orientation of mitotic APs (i.e. perpendicular to their apical-basal axis) predicts the delamination from the VZ of either one or both of the daughter cells[34,35]. Using high resolution images of the DAPI– and SOX2–stained AP anaphase nuclei at the ventricular surface (marked with ZO-1), we therefore determined mitotic AP cleavage plane angles relative to the apical surface (Fig. 4A, B). We categorized AP anaphase cleavage plane angels into three groups: (1) 90-61° as vertical cleavage, (2) 60-31° as oblique cleavage; (3) 30-0° as horizontal cleavage. We found a massive switch of the predominant cleavage plane orientation from vertical to horizontal in the mitotic APs of BWCFF-S cerebral organoids in comparison to those of control cerebral organoids (Fig. 4C,D). This change in cleavage plane orientation no longer allows APs to undergo symmetric–proliferative divisions to increase their pool size, and strongly suggests an increase in the delamination of cells from the VZ in BWCFF-S cerebral organoids, providing a likely underlying mechanism for the reduction in the size of the VZ progenitor pool of these organoids.

Alterations in tubulin concentration at the apical cell cortex likely provide an explanation for the change in cleavage plane orientation of mitotic APs in BWCFF-S organoids

Changes in the orientation of the cleavage plane are known to be caused by changes in the orientation of the mitotic spindle[36-39]. Mitotic spindle positioning in turn involves the interaction of the astral microtubules with the cell cortex, notably with microtubule-binding proteins[36,38,40,41]. We therefore explored, by transmission electron microscopy and tubulin

immunohistochemistry, whether the BWCFF-S cerebral organoids expressing either the *ACTB* or *ACTG1* variant showed alterations in microtubule structure or tubulin concentration at the cell cortex of VZ progenitors. On transmission electron microscopy, in the BWCFF-S organoids, we observed a higher density of microtubule bundles at the apical cell cortex that appeared to be anchored to the adherens junction belt besides being nucleated at the basal body of the cilium (Fig. 5A).

As the cell cortex in the vicinity of the adherens junctions of VZ progenitors is known to have a key role for the positioning of the mitotic spindle parallel to the ventricular surface, and hence for ensuring a vertical cleavage plane[36-39], we investigated this issue further and performed tubulin immunohistochemistry. This revealed a striking concentration of both alpha- and beta-tubulin at the apical cell cortex of the VZ progenitors in the BWCFF-S organoids (Fig. 5B). It therefore seems likely that this concentration of tubulin and microtubules at the adherens junction-near, apical cell cortex of the BWCFF-S VZ progenitors results in an altered occupation, upon AP mitosis, of astral microtubule binding sites such that a positioning of the mitotic spindle parallel to the ventricular surface is hindered. This in turn would result in the observed switch of the cleavage plane of mitotic APs from a predominant vertical to a predominant horizontal orientation, preventing an increase in the pool size of APs via their symmetric–proliferative divisions and leading to increased cell delamination from VZ in the BWCFF-S organoids.

BWCFF-S–like *ACTB* Thr120Ile mutant cerebral organoids generated from CRISPR/Cas9-edited control CRTDi011-A iPSCs show essentially the same phenotypes as BWCFF-S *ACTB* Thr120Ile patient-derived cerebral organoids.

In light of the (unavoidable) facts (see Methods) that (i) the reprogramming of the control or BWCFF-S patient–derived fibroblasts had to be carried out at three different institutes, (ii) the culture conditions after reprogramming until the isolation of the iPSC clones were similar but not identical, and (iii) the genetic backgrounds of the healthy donor and the two BWCFF-S

patients were (by definition) different, it was essential to demonstrate that the phenotypes observed in the BWCFF-S cerebral organoids as compared to control organoids were not due to these differences but indeed caused by the point mutations in *ACTB* or *ACTG1*. To this end, we subjected the control CRTDi011-A iPSCs to CRISPR/Cas9-mediated genome editing to introduce a single point mutation into *ACTB* which would selectively result in the Thr120Ile change. We then isolated two clones after this genome editing, referred to as CRTDi011-A–mut*ACTB*-1 and CRTDi011-A–mut*ACTB*-2, and used these to generate cerebral organoids, collectively referred to as cr. *ACTB* Thr120Ile organoids. Analyses in comparison to the control CRTDi011-A iPSC–derived organoids of (i) the organoid area, (ii) the VZ radial thickness, perimeter, and area, (iii) the number of VZ cells per ventricle-like structure, and (iv) anaphase AP cleavage plane angles, revealed essentially the same phenotypes in the cr. *ACTB* Thr120Ile organoids as observed in the BWCFF-S *ACTB* Thr120Ile patient-derived organoids (Fig. 6). These data indicate that the phenotypes observed in the BWCFF-S *ACTB* Thr120Ile patient-derived cerebral organoids were indeed caused by the point mutation in *ACTB*.

Conclusion

In conclusion, our results indicate that cerebral organoids expressing BWCFF-S–associated mutant *ACTB* or *ACTG1* genes provide insight into the cellular mechanism underlying the cortical malformations seen in BWCFF-S patients. Thus, BWCFF-S organoids exhibit alterations of the tubulin/microtubule organization at the apical cell cortex of VZ progenitors. This leads to changes in the orientation of the AP mitotic spindle from predominantly parallel to predominantly perpendicular to the ventricular surface. This in turn is incompatible with AP proliferation increasing AP abundance, and likely results in an increased delamination of cells from the VZ due to a change in the orientation of the cleavage plane of mitotic APs from predominantly vertical to predominantly horizontal. This lack of AP proliferation and increase in cell delamination from the VZ causes a decrease in the size of the VZ within the ventricle-like structures of the BWCFF-S cerebral organoids. As the VZ constitutes a substantial portion of the mass of the organoids, and as the decrease in VZ size does not appear to be

compensated by a corresponding size increase of non-VZ tissue, BWCFF-S cerebral organoids are reduced in their total size, consistent with the microcephalic cortical malformations seen in BWCFF-S patients.

Discussion

The present study provides crucial insight into the pathogenesis underlying the cortical malformations that are observed in patients afflicted with Baraitser-Winter-CerebroFrontoFacial syndrome (BWCFF-S) and are associated with the pathogenic variants of the *ACTB* and *ACTG1* genes encoding the actin isoforms βCYA and γCYA, respectively. Patients with BWCFF-S exhibit a variety of cortical anomalies; most common are microcephaly and malformations of the lissencephaly spectrum[42]. In short, the use of cerebral organoids grown from BWCFF-S patient-derived iPSCs carrying either *ACTB* or *ACTG1* mutations has revealed that one of the early steps in the formation of the BWCFF-S-associated microcephaly is cytoskeletal disorganization changing AP mitotic spindle orientation. This prevents the proliferation of APs and likely increases cell delamination from the VZ, resulting in a reduction in the size of the VZ progenitor pool of these organoids. Three aspects of our study deserve particular attention, (i) the appropriateness of cerebral organoids grown from BWCFF-S patient-derived iPSCs to model the pathogenesis of the cortical malformation observed in BWCFF-S patients; (ii) a likely mechanism explaining how the mutant actin isoforms βCYA and γCYA cause the formation of BWCFF-S-associated microcephaly; and (iii) a potential link between the actin and microtubule cytoskeletons in relation to mutant actin.

First, multiple studies demonstrated that cerebral organoids exhibit many aspects of *in vivo* corticogenesis[15,16,43,44] (for review, see[20]). Although cerebral organoids have been successfully used to model various types of malformations of cortical development, the modelling of an actin-related pathology required an additional caution as actin isoforms display a tightly regulated time- and tissue-specific expression pattern[45]. In fetal human neocortex, both actin isoforms, βCYA and γCYA, show a widespread distribution across the entire cortical wall. Similar to this, cerebral organoids show a widespread distribution across the entire wall of the ventricle-like structures, in principle allowing the study of neurodevelopment defects of actinopathies, such as BWCFF-S, in this 3D model of cortical development. Indeed, the BWCFF-S-associated microcephaly is recapitulated in BWCFF-S patient-derived cerebral

organoids by a significant reduction in organoid size. In summary, cerebral organoids grown from BWCFF-S patient-derived iPSCs are suitable to model the pathogenesis of cortical malformations observed in BWCFF-S patients.

Second, with regard to a likely mechanism underlying BWCFF-S-associated cortical malformations, only very few neuropathological reports are currently available (for review, see[46]). In one of these reports the fetal brain from a pregnancy terminated after the diagnosis of BWCFF-S was analyzed[12]. This brain showed a reduced number and poor organization of neurons in the cortical plate[12]. Interestingly, the published fetus carried exactly the same missense variant in *ACTG1*:p.Thr203Met as the patient who donated the skin biopsy for iPSC reprogramming and cerebral organoid generation in this study. In line with the clinical and neuropathological data, cerebral organoids with the *ACTG1*:p.Thr203Met variant as well as organoids with the *ACTB* mutation had significantly reduced size, recapitulating microcephaly in BWCFF-S patients. As a potential mechanism of this size reduction in BWCFF-S patient-derived organoids, we identified a switch of the mitotic AP cleavage plane from a predominant vertical to a predominant horizontal orientation, preventing the proliferation of APs that would increase their abundance and thereby the VZ progenitor pool, and likely leading to increased cell delamination from the VZ of BWCFF-S organoids.

In this context, it is important to emphasize that the phenotypes observed in the BWCFF-S cerebral organoids when compared to control cerebral organoids were not due to differences other than the mutations in the actin genes, such as differences in the generation of the control and patient-derived iPSC clones used to generate the cerebral organoids, or differences in the genetic backgrounds between the healthy donor and the two BWCFF-S patients. Specifically, organoids generated from genome-edited clones that were derived from the control iPSC line CRTDi011-A, in which a single point mutation into *ACTB* had been introduced that would selectively result in the Thr120Ile change, showed essentially the same phenotypes compared

to control as those observed in the BWCFF-S *ACTB* Thr120Ile patient-derived organoids, demonstrating that the latter phenotypes were indeed caused by the point mutation in *ACTB*.

This phenotype is presumably caused by an increased concentration of tubulin and microtubules at the adherens junction-near, apical cell cortex of the BWCFF-S VZ progenitors and likely results, upon AP mitosis, in an altered occupation of astral microtubule binding sites such that a positioning of the mitotic spindle parallel to the ventricular surface is hindered. Several seminal studies have established that during cell division, actin and microtubules work closely together and should be considered as a unified system in which subcomponents co-regulate each other[47]. Our observation of horizontal cleavage planes prevailing in mitotic APs of BWCFF-S cerebral organoids does not only provide a potential mechanism of the reduced brain size in BWCFF-S patients, but also underlines an extensive actin–microtubule crosstalk. It is well described that mutations in the tubulin-encoding genes *TUBA1A* and *TUBB2B*, in genes encoding multiple microtubule-associated proteins (e.g. *LIS1* and *DCX*), and also in genes encoding for actin and actin-binding proteins, all result in a similar spectrum of malformations of cortical development (for review, see[48]). For example, two organoid-based studies of the Miller-Dieker syndrome (heterozygous deletion of chromosome 17p13.3 involving the genes *LIS1* and *YWHAE*) reported a switch from horizontal to vertical cleavage plane orientation of APs[27,28], essentially the same pathology that we observed in BWCFF-S associated with actin mutations. Hence, our work provides further evidence that a substantial number of malformations of cortical development represent cytoskeletal disorders with mutations affecting different cytoskeletal components disrupting the same cellular functions.

Third, with regard to a potential link between actin and microtubule cytoskeletons in relation to mutant actin, a previous study has already demonstrated a significant impact of mutant beta actin on the microtubule cytoskeleton organization in patient-derived megakaryocytes and platelets[8]. This included a loss of the so-called tubulin ring required for an efficient division of the proplatelet into two mature thrombocytes, without an effect on the proliferation of

megakaryocytes[8]. In BWCFF-S patient-derived cerebral organoids, mutant actin isoforms βCYA and γCYA led to a substantial microtubule disorganization during interphase and in mitosis. Moreover, we found a significant accumulation of microtubules at the apical cell cortex of VZ progenitors. The reason for, and the mechanisms of, the microtubule accumulation are currently not yet known. Considering the possibility that the growing microtubules might be "captured" and "capped" and therefore stabilized by different targets within the cell (search and capture hypothesis)[49-51], we hypothesize that the presence of the mutant actin isoforms changes the properties of the cell cortex, facilitating capture and selective stabilization of microtubules at the cell cortex and at adherence junctions. This would result in an increased number of stabilized microtubules at the apical cell cortex of mitotic APs, impede the proper positioning of the poles of the mitotic spindle, and might disturb the interaction of the astral microtubules with the actin cytoskeleton, resulting in a switch from vertical to horizontal cleavage plane orientation.

Taken together, our results demonstrate the suitability of cerebral organoids as models for actinopathies and for identifying the underlying mechanisms for the development of cortical malformations of one of these actinopathies, BWCFF-S.

Methods

Reprogramming of somatic cells (fibroblasts) to generate control and BWCFF-S patient-derived induced pluripotent stem cells (iPSCs)

After obtaining a positive statement (EK127032017 and EK44012019) from the ethics council of TU Dresden, fibroblasts were isolated, using a previously described procedure[8] , from skin punch biopsies of a healthy adult female donor (control) and of two female BWCFF-S patients carrying either the NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile or the NM_001614.5(*ACTG1*):c.608C>T p.Thr203Met mutation. The presence of both BWCFF-S mutations was confirmed with locus-specific Sanger sequencing as previously described[29].

The three batches of isolated human fibroblasts were put into culture under identical conditions (in BIO-AMF™-2 medium (Biological Industries)), grown for 2-3 passages, and then subjected to reprogramming to generate iPSCs. Fibroblasts from the BWCFF-S mutant *ACTB* patient were frozen in liquid nitrogen before reprogramming. Due to differences in the availability of the healthy donor and the two BWCFF-S patients providing the skin punch biopsies, this reprogramming was performed correspondingly at three different locations. The human control fibroblasts were reprogrammed at the CRTD Stem Cell Engineering Facility at the *Technische Universität Dresden*. The fibroblasts from the BWCFF-S patient carrying the NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile mutation were reprogrammed at the *Medizinische Hochschule Hannover*. The fibroblasts from the BWCFF-S patient carrying the NM_001614.5(*ACTG1*):c.608C>T p.Thr203Met mutation were reprogrammed at the *Medizinisch Theoretisches Zentrum Dresden*. All reprogrammings were performed using the same type of kit, the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific).

Human control fibroblasts were transduced according to the reprogramming kit manufacturer's instructions. After 5 days following transduction, cells were plated onto irradiated CF1 Mouse

Embryonic Fibroblasts (Thermo Fisher Scientific) and cultured in ReproTeSR (StemCell Technologies), After 10 days of culture, individual iPSC colonies were mechanically picked and expanded as clonal lines on Matrigel-coated cell culture dishes (Corning) in mTeSR™1 (StemCell Technologies). IPSC lines were passaged using ReLeSR (StemCell Technologies).

BWCFF-S *ACTB* Thr120Ile patient-derived fibroblasts were thawed in fibroblast medium I (DMEM (Gibco), supplemented with 10% FCS (PAA), 1% MEM non-essential amino acids (Gibco) and 1 mM L-glutamine (Gibco), cultured for 3 days, and then transduced according to the reprogramming kit manufacturer's instructions. After 4 days following transduction, cells were plated on mitotically inactivated murine embryonic feeder cells and cultured in iPSC medium (knockout-DMEM (Gibco), supplemented with 20% knockout serum replacement (Gibco), 1 mM L-glutamine (Gibco), 0.1 mM 2-mercaptoethanol (Gibco), 1% MEM non-essential amino acids (Gibco) and 8 ng/ml bFGF-2 (PeproTech)). After 8 days of culture, individual iPSC colonies were mechanically picked and expanded as clonal lines on murine embryonic feeder cells in iPSC medium. IPSC lines were passaged using collagenase IV (Gibco).

BWCFF-S *ACTG1* Thr203Met patient-derived fibroblasts were transduced according to the reprogramming kit manufacturer's instructions. Directly after transduction, cells were cultured in fibroblast medium II (DMEM/F-12 (Gibco), supplemented with 1% GlutaMAX Supplement (Gibco), 20 ng/ml hbFGF (PeproTech), 1% 2-mercaptoethanol (Serva), 10% FBS (Sigma-Aldrich) and 1% MEM non-essential amino acids (Gibco). After 7 days of culture, the cells were passaged on Geltrex-coated cell culture dishes (Thermo Fisher Scientific) in fibroblast medium II. One day after, the medium was changed to Essential 8™ Medium (Gibco). Individual iPSC colonies were mechanically picked and expanded as clonal lines on Geltrex-coated cell culture dishes in Essential 8™ Medium, supplemented with 2 µM thiazovivin for 24 h (Sigma-Aldrich). IPSC lines were passaged using versene solution (Thermo Fisher Scientific).

Although there were some differences in cell culture conditions after the reprogramming step, as can be tracked above, these are unlikely be responsible for the phenotypic differences observed with the various cerebral organoids described in the Results section. The same applies to the different genetic background of the healthy donor and the two BWCFF-S patients, in light of the following considerations. All iPSC clones obtained from the healthy donor- and the two BWCFF-S patient-derived fibroblasts were treated identically after the clonal expansion step (see below). All iPSC clones were tested for the removal of Sendai virus genomes and transgenes by reverse transcription-PCR analysis, and further checked for pluripotency marker expression, differentiation to three germ layers and an intact karyotype by G-banding (data not shown). One fully characterized clone of the control iPSC line (referred to as CRTDi011-A) and two clones per mutation (referred to as mut*ACTB*-1 and mut*ACTB*-2, and as mut*ACTG1*-1 and mut*ACTG1*-2) were used for cerebral organoid generation. Moreover, the presence of the NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile and NM_001614.5(*ACTG1*):c.608C>T p.Thr203Met mutation was additionally confirmed by locus-specific Sanger sequencing of the two clones each used in this study.

Furthermore, strong evidence that the phenotypic differences between the mut*ACTB*-1–, mut*ACTB*-2–, mut*ACTG1*-1– and mut*ACTG1*-2–derived cerebral organoids and the control organoids are caused by the mutations in *ACTB* and *ACTG1*, respectively, is provided by our finding that introducing the Thr120Ile change into *ACTB* in the control iPSC clone CRTDi011-A using the CRISPR/Cas9 technology is sufficient to cause essentially the same cerebral organoid phenotype as observed in the BWCFF-S *ACTB* Thr120Ile patient-derived cerebral organoids (Fig. 6).

CRISPR/Cas9-mediated generation of *ACTB* Thr120Ile mutant iPSCs from control CRTDi011-A iPSCs

For the target region NC_000007.14:g.5529165G>A (NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile) , the sequence was analyzed for appropriate guide RNA binding sites using the

Geneious software and the CRISPOR design webtool (http://crispor.tefor.net/). The selected target sequence plus PAM was: 5'-AGGTAGCGGGCCACTCACCTGGG-3'. Guide RNA was ordered as crRNA from IDT (Integrated DNA Technologies). Linear donor templates with 50-bp homology arms were purchased from IDT as PAGE Ultramer ssDNA oligonucleotides with three phosphorothioated DNA bases on each side. In order to generate a heterozygous iPSC line, two oligonucleotides were designed; one contained the point mutation c.359C>T, whereas the other contained the sequence encoding the reference amino acid sequence, with both oligonucleotides containing silent mutations to prevent recutting of either targeted allele. The ss-oligodeoxynucleotide (ssODN) sequence for the c.359C>T mutation was: 5'-AGGAGCACCCCGTGCTGCTGACCGAGGCCCCCCTGAACCCCAAGGCCAACAGGGAAA AAATGA**T**ACAGGTGAGTGGCCCGCTACCTCTTCTGGTGGCCGCCTCCCTCCTTCCTGG-3'. The ssODN sequence for the c.359C>C reference maintenance was: 5'-AGGAGCACCCCGTGCTGCTGACCGAGGCCCCCCTGAACCCCAAGGCCAACAGGGAAA AAATGA**C**ACAGGTGAGTGGCCCGCTACCTCTTCTGGTGGCCGCCTCCCTCCTTCCTGG-3' (underlined bases indicate match to guide RNA). CRTDi011-A cells were transfected with RNP (46 pmol guideRNA and 31 pmol Cas9) and 0.5 µl of each ssODN (100 µM stock, yielding 50 pmol final amount) using the NEON transfection system (settings: 1000 V, 20 ms, 1 pulse). Cells were single-cell sorted by FACS, and heterozygous single-cell clones were identified by Sanger Sequencing of the target region (primer_fwd: 5'-GTCACCAACTGGGACGACAT-3', primer_rev: 5'-GCTAAGTGTGCTGGGGTCTT-3'). Two such clones, referred to as CRTDi011-A–mut*ACTB*-1 and CRTDi011-A–mut*ACTB*-2, were used for the generation of cerebral organoids.

iPSC culture

The clonal control iPSC lines SC102A-1 (System Biosciences) and CRTDi011-A (this study), the mutated CRTDi011-A–derived clones CRTDi011-A–mut*ACTB*-1 and CRTDi011-A–mut*ACTB*-2, and the BWCFF-S patient-derived iPSC lines BWCFF-S *ACTB* Thr120Ile (clones mut*ACTB*-1 and mut*ACTB*-2) and BWCFF-S *ACTG1* Thr203Met (clones mut*ACTG1*-1 and

mut*ACTG1*-2) (all this study) were subjected to an identical culture protocol under feeder-free conditions on Matrigel-coated plates (Corning) in mTeSR™1 (StemCell Technologies) at 37°C, in a humidified atmosphere of 5% CO_2 and 95% air. Medium was changed daily and cells were passaged every third day, using ReLeSR™ (StemCell Technologies).

Generation of cerebral organoids

Cerebral organoids were generated as previously described[16,33,52,53] with minor modifications. Patient-derived organoids were generated from 2 clones each per mutation (clones mut*ACTB*-1 and mut*ACTB*-2, and clones mut*ACTG1*-1 and mut*ACTG1*-2), patient-like organoids were generated from the mutated CRTDi011-A–derived clones CRTDi011-A–mut*ACTB*-1 and CRTDi011-A–mut*ACTB*-2, control organoids were generated from 2 different iPSCs (line SC102A-1 and clone CRTDi011-A) using feeder-free conditions. Briefly, 9,000 cells/well were seeded into an ultra-low-attachment 96-well plate (Corning) in mTeSR™1 (StemCell Technologies) supplemented with 50 µM ROCK inhibitor Y-27632 (StemCell Technologies). After 48h, medium was changed to mTeSR™1 without ROCK inhibitor Y-27632. On day 5, mTeSR™1 was replaced by neural induction medium (DMEM/F12 (Gibco), 1% N2 supplement (Gibco) 1% GlutaMAX supplement (Gibco), 1% MEM non-essential amino acids (Gibco), and 1 mg/ml heparin (Sigma-Aldrich)) and changed every other day. Five days later, embryoid bodies were embedded in Matrigel, medium was changed to differentiation medium (DMEM/F12 and Neurobasal (Gibco, ratio 1:1), 0.5% N2 supplement (Gibco) 1% GlutaMAX supplement (Gibco), 0.5% MEM non-essential amino acids (Gibco), insulin (2.875 ng/ml final concentration Sigma-Aldrich), 1% B27 supplement (without vitamin A, Gibco), 0.00035% 2-mercaptoethanol (Serva), and 1% penicillin-streptomycin (Gibco)), and cerebral organoids were further cultivated on an orbital shaker. Medium was changed every other day. On day 16, medium was changed to differentiation medium containing 1% B27 supplement with vitamin A (Gibco), und organoids were cultivated under these conditions until day 30 and 50 after seeding.

Fixation and cryosectioning of cerebral organoids

Cerebral organoids were fixed after 30 and 50 days in culture in 4% paraformaldehyde (PFA) in 120 mM phosphate buffer (pH 7.4) for 1 h at room temperature and then washed in PBS for at least 12 h. Organoids were then incubated overnight in phosphate-buffered saline (PBS) containing 30% sucrose at 4°C, embedded in Tissue-Tek OCT (Sakura, Netherlands) and frozen on dry ice. Cryosections of 12 µm thickness were cut on a cryostat (Microm HM 560, Thermo Fisher Scientific) and stored at –20°C until further use.

Fixation, paraffin embedding and sectioning of fetal human brain tissue

Fetal human brain samples were collected in accordance with the Helsinki Declaration 2000 and approval of the Ethical Committees of the School of Medicine, University of Zagreb, and University Hospital Centre Zagreb (641-01/19-02/01; 8.1-7/170-02; 02/21AG). The brain specimens were obtained from fetuses following spontaneous abortions (with twelve hours postmortem delay, or less). The deaths were attributed to respiratory distress syndrome or non-fetal causes. Two human fetuses at the age of 12 wpc and two human fetuses at the age of 16 wpc were clinically evaluated by a gynecologist and a pathologist and included in this study. The fetuses showed no evidence of growth restriction or developmental malformations, the fetal age was estimated based on the crown-rump length, pregnancy records, and assessment of histological sections. Whole fetal brains were fixed in 4% PFA in 0.1 M PBS pH 7.4 for 48 to 96 h depending on the brain size, and afterwards embedded in paraffin according to standard procedures. The brain tissue was cut into 20-µm thick sections, mount on glass slides, deparaffinized and rehydrated prior to immunohistochemistry as described below.

Fixation and cryosectioning of fetal human brain tissue

Fetal human brain tissue was obtained from the Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Carl Gustav Carus of the Technische Universität Dresden with maternal agreement and permission of the Ethics committee at the TU Dresden. After pregnancy termination the tissue was directly transferred to the lab, and fragments of the

cerebral cortex were identified by morphology and fixed in 4% PFA in 120 mM phosphate buffer pH 7.4 for 3 h at room temperature followed by 24 h at 4°C. The specimen was then incubated overnight in PBS containing 30% sucrose at 4°C and processed for cryosectioning as described above for cerebral organoids.

Immunohistochemistry

For immunohistochemical detection of βCYA and γCYA, cerebral organoids and fetal brain sections were washed twice with PBS und permeabilized with ice-cold methanol (–20°C) for 5 min. After two washing steps in PBS, samples were incubated in blocking buffer (2% BSA/PBS) for 1 h. Primary antibodies were diluted in blocking buffer and incubated for 1 h, followed by a 1 h incubation with secondary antibodies also diluted in blocking buffer[8]. Immunostained tissue sections were counterstained with DAPI and were mounted in Mowiol (Millipore). Other immunohistochemical stainings were performed as previously described[52] using antigen retrieval in 0.01 M sodium citrate buffer (pH 6.0) for 1 h at 70°C. The following primary antibodies were used (see also Suppl. Table 1 for details): mouse monoclonal IgG_1 anti-βCYA (Bio-Rad, clone 4C2, RRID:AB_2571580), mouse monoclonal IgG_{2b} anti-γCYA (Bio-Rad, clone 2A3, RRID:AB_2571583), mouse anti-Caspase3 (abcam, #ab208161), rat anti-CTIP2 (abcam, #ab18465, RRID:AB_2064130), rabbit anti-Ki-67 (abcam, #ab15580, RRID:AB_443209), rabbit anti-Nestin (Sigma-Aldrich, #N5413, RRID:AB 1841032), mouse anti-pan-actin (Novus Biologicals, #NB600-535, RRID:AB_2222881), mouse anti-pan-cadherin (Sigma-Aldrich, #C1821, RRID:AB_476826), rat anti-PH3 (abcam, #ab10543, RRID:AB_2295065), goat anti-SOX2 (R+D Systems, #AF2018, RRID:AB_355110), rabbit anti-TBR2 (abcam, #ab23345, RRID:AB_778267), mouse anti-alpha-tubulin (Sigma-Aldrich, #T6199, RRID:AB_477583), rabbit anti-beta-tubulin (abcam, #ab179513), mouse anti-Tuj1 (BioLegend, #801201, RRID:AB_2313773) and rabbit anti-ZO-1 (Invitrogen, #61-7300, RRID:AB_138452). All fluorescent-conjugated secondary antibodies were purchased from Thermo Fisher Scientific (Suppl. Table 1).

Image acquisition

Images were acquired as Z-stacks of thirty 0.3-µm optical sections in the case of βCYA and γCYA immunostainings or of twelve 1-µm optical sections in the case of all other immunostainings using a Zeiss LSM 880 microscope with a 63x/1.3 LCI Plan-Neofluar, W/Glyc, DIC (Zeiss) objective. Prior to the image analysis, 10 adjacent slices in the center of the stack of the thirty 0.3-µm optical sections of the βCYA and γCYA immunostainings, and 3 adjacent slices in the center of the stack of the twelve 1-µM slices of all other immunostainings, were averaged. Overview images of the cerebral organoids were acquired using a Keyence's bench-top BZ-X810 all-in-one fluorescence microscope with 2x Plan-Apochromat, air, and 10x Plan-Fluor, air objectives (Keyence). Haze reduction function (Keyence) for the elimination of fluorescence blurring was used for overview images of DAPI-stained cerebral organoids.

Analysis of the βCYA and γCYA distribution

Analysis of the βCYA and γCYA distribution was performed with custom Jython scripts written for Fiji[54]. The input image stacks containing the γCYA isoform images in the magenta channel, the βCYA isoform images in the green channel and an additional DAPI channel were first corrected for shifts caused by chromatic aberrations. Then, background intensity was subtracted per channel and incompletely acquired images at the beginning and end of the stack were removed. These preprocessed image stacks were re-sliced along the z-axis for visualization purposes. To obtain the βCYA and γCYA distributions in the x-y plane, ten adjacent slices in the center of the stack were averaged. The gray-scale images to visualize the difference in localization pattern of γCYA and βCYA were obtained by first normalizing the intensities of each channel (histogram normalization). Then, the green channel signals were subtracted from the magenta channel signals, and a gray lookup-table was applied. Thus, bright regions corresponded to areas in which γCYA was localized relatively stronger (compared to the localization distribution of βCYA). Conversely, in dark regions, βCYA was predominantly localized. Note that the generated images visualize relative localization patterns and do not quantify absolute concentrations of γCYA or βCYA.

In a second analysis step the differences between the γCYA and βCYA localization patterns were quantified. Within each of the various zones (AJ, VZ, iSVZ, oSVZ, IZ, CP, MZ) of fetal human neocortical tissue, a region of interest (ROI) was defined for which the relative localization of βCYA and γCYA was compared. To this end, the ratio between the mean signal intensities of the respective ROI was calculated for each channel separately. Differences in the value of the ratio for the two channels then indicated a different localization preference of γCYA versus βCYA. For statistical analysis, intensity ratios of multiple images were obtained and compared with GraphPad Prism. The relative intensities of γCYA and βCYA were normalized to the mean fluorescence intensity of all positions.

Quantifications

Progenitor terminology. We use the term "VZ progenitors" as a collective term for both, (i) the apical progenitors (APs) in the VZ, i.e. the canonical class of progenitors residing in the VZ, and (ii) AP-derived newborn basal progenitors, which are also found in the VZ prior to their migration to the subventricular zone (SVZ). We restrict the term "APs" to those VZ progenitors that undergo mitosis at the ventricular surface, which is a defining criterion for APs.

The contour of a cerebral organoid as it appeared in a bright-field image (see, for example the top rows in Fig. 2 A,B) was used to determine the cerebral organoid area. For determining the radial thickness of the VZ, the mean of 4 measurements of the VZ, made at orthogonal and opposite positions within a ventricle-like structure (see Fig. 3A), was calculated. The VZ perimeter was defined as the basal boundary of the VZ of a given ventricle-like structure. To calculate the area of the VZ, the area encompassed by the VZ perimeter was measured and the area of the ventricular lumen (see Fig. 3A) was subtracted. For determining the number of VZ progenitors per ventricle-like structure and the cell density of the VZ, the number of DAPI-stained nuclei in the VZ of all ventricle-like structures of the number of cerebral organoids indicated in the Fig. legends was counted. For quantifying these five parameters, the data of

all ventricle-like structures per single organoid were averaged prior to calculating the mean for the organoids of a given condition. For quantification of cleavage plane angles, the indicated number of mitotic APs in anaphase were analyzed from control IPSC- (lines SC102A-1 and CRTDi011-A) derived organoids, patient-like organoids from the mutated CRTDi011-A–derived clones CRTDi011-A–mut*ACTB*-1 and CRTDi011-A–mut*ACTB*-2, and patient-derived cerebral organoids (clones mut*ACTB*-1 and mut*ACTB*-2, and clones mut*ACTG1*-1 and mut*ACTG1*-2). The proportion of cycling cells in the VZ was defined as the percentage of DAPI-stained nuclei in the VZ that were Ki-67^{+}. Mitotic cells in the VZ, i.e. mitotic APs, were expressed as the number of PH3^{+}-stained cells per VZ area. All quantifications were performed by using Fiji[54].

Conventional transmission electron microscopy (EM)

Electron microscope analysis was performed as previously described[55-57]. Cerebral organoids were shortly pre-fixed in 0.2% glutaraldehyde in culture medium, before being fixed in 1% glutaraldehyde, 2% PFA in 0.1 M Pipes pH 7.4, 0.09 mM $CaCl_2$ for 1 h at room temperature. After washing steps, the samples were transferred into 4% low melting agarose in PBS. Sections of 200 µm thickness through the cerebral organoids were cut on a vibratome (Leica VT1200S). Sections were post-fixed with 2% osmium tetroxide (OsO_4), 1.5% potassium ferrocyanide for 30 min at room temperature. Contrast was enhanced by subsequent incubation (without washing) with 1% OsO_4 for 1 h. After washing, the samples were stained en bloc with 0.5% uranyl acetate overnight at 4°C. Samples were dehydrated by an ascending series of ethanol (15 min for each step) and three times in pure ethanol. After gradual infiltration with resin, the samples were flat-embedded in Epon replacement (Embed-812, Science Services) and polymerized at 60°C.

Selected regions were re-mounted on resin stubs and 70 nm-thick sections were cut on an ultramicrotome (Leica UCT). Sections were post-stained with uranyl acetate and lead citrate according to standard protocols. Images were acquired on a Tecnai 12 Biotwin transmission

electron microscope (Thermo Fisher Scientific/FEI) at 100 kV with a TVIPS F416 CMOS camera and SerialEM software[58]. Image processing was performed in Fiji[54].

Statistical analysis

GraphPad Prism version 9.3.1 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com) was used for graphical illustration and statistical analysis of all data. All data were tested for normal distribution (Shapiro-Wilk test) and further analyzed with unpaired *t*-test, Mann-Whitney *U* test, one-way or two-way ANOVA or Kruskal-Wallis-Test (*, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$).

Acknowledgements

We thank J. Peychl and his team of the Light Microscopy Facility at MPI-CBG for help with microscopy and the Light Microscopy Facility, a Core Facility of the CMCB Technology Platform at TU Dresden, for scanning of cryosections. We thank Christina Eugster Oegema and Jula Peters of the Organoid and Stem Cell Facility at MPI-CBG for the help in parallel culture of multiple organoid batches as well as sample preparation and Jana Meissner and Jula Peters for their help in sample preparation for EM. We also thank Ilka Reinhardt and Mihail Sarov of the Genome Engineering Facility at MPI-CBG for the generation of *ACTB* Thr120Ile mutant iPSCs from control CRTDi011-A iPSCs.

I.N. was a doctoral student jointly supervised by N.D.D. and M.H. E.S. was a fellow of MPI-CBG. Work in the NJM group (collection and research on the postmortem fetal human brains) was funded by Croatian Science Foundation project IP-2019-04-3182 at Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (GA KK01.1.1.01.0007) funded by the European Union through the European Regional Development Fund). Collaboration between NDD and NJM was funded throughout COST Action NeuroMIG 16118. Work in the laboratory of W.B.H. was supported by grants from the DFG (SFB 655, A2), the ERC (250197) and ERA-NET NEURON (MicroKin). Work in the NDD group was supported by grants from the DFG (DI 2170/3-1 and DI 2170/5-1), and EJPRD JTC 2019 (PredACTINg; BMBF 01GM1922A). M.H. was supported by an ERC starting grant (101039421).

Contributions

IN: Investigation, visualization, methodology, data curation, writing

MWB: Investigation (TEM), methodology, writing

FMB: Validation, writing – review & editing

MBR: Resources (fetal samples), investigation, visualization

VR: Resources (tissue donor recruitment)

MMP: Resources, investigation (pathological examination of the fetal brains)

PW: Resources (tissue donor recruitment)

MS: Resources (patient recruitment), visualization

AH and UM: Resources (iPSC line NM_001101.5(*ACTB*):c.359C>T p.Thr120Ile)

KK and KG: Resources (iPSC line NM_001614.5(*ACTG1*):c.608C>T p.Thr203Met)

KN: Resources (iPSC line CRTDi011-A)

NW: Software, methodology

ES: Writing – review & editing, funding acquisition

NJM: Resources, methodology, writing – review & editing, funding acquisition, supervision

WBH: Conceptualization, methodology, writing, funding acquisition, supervision

NDD: Resources (patient recruitment), project administration, writing, funding acquisition, supervision

MH: Conceptualization, writing, methodology, funding acquisition, supervision

References

1. Perrin, B.J. & Ervasti, J.M. The actin gene family: function follows isoform. *Cytoskeleton (Hoboken)* **67**, 630-4 (2010).
2. Pollard, T.D. & Cooper, J.A. Actin, a central player in cell shape and movement. *Science* **326**, 1208-12 (2009).
3. Vandekerckhove, J. & Weber, K. At least six different actins are expressed in a higher mammal: an analysis based on the amino acid sequence of the amino-terminal tryptic peptide. *J Mol Biol* **126**, 783-802 (1978).
4. Parker, F., Baboolal, T.G. & Peckham, M. Actin mutations and their role in disease. *Int J Mol Sci* **21**(2020).
5. Riviere, J.B. *et al.* De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. *Nat Genet* **44**, 440-4, S1-2 (2012).
6. Verloes, A. *et al.* Baraitser-Winter cerebrofrontofacial syndrome: delineation of the spectrum in 42 cases. *Eur J Hum Genet* **23**, 292-301 (2015).
7. Cuvertino, S. *et al.* ACTB Loss-of-Function mutations result in a pleiotropic developmental disorder. *Am J Hum Genet* **101**, 1021-1033 (2017).
8. Latham, S.L. *et al.* Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopenia. *Nat Commun* **9**, 4250 (2018).
9. Di Donato, N. *et al.* Update on the ACTG1-associated Baraitser-Winter cerebrofrontofacial syndrome. *Am J Med Genet A* **170**, 2644-51 (2016).
10. Forman, M.S., Squier, W., Dobyns, W.B. & Golden, J.A. Genotypically defined lissencephalies show distinct pathologies. *J Neuropathol Exp Neurol* **64**, 847-57 (2005).
11. Poirier, K. *et al.* Rare ACTG1 variants in fetal microlissencephaly. *Eur J Med Genet* **58**, 416-8 (2015).
12. Vontell, R. *et al.* Post-mortem characterisation of a case with an ACTG1 variant, agenesis of the corpus callosum and neuronal heterotopia. *Front Physiol* **10**, 623 (2019).

13. Cheever, T.R. & Ervasti, J.M. Actin isoforms in neuronal development and function. *Int Rev Cell Mol Biol* **301**, 157-213 (2013).

14. Belyantseva, I.A. *et al.* Gamma-actin is required for cytoskeletal maintenance but not development. *Proc Natl Acad Sci U S A* **106**, 9703-8 (2009).

15. Kadoshima, T. *et al.* Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proc Natl Acad Sci U S A* **110**, 20284-9 (2013).

16. Lancaster, M.A. *et al.* Cerebral organoids model human brain development and microcephaly. *Nature* **501**, 373-9 (2013).

17. Lancaster, M.A. *et al.* Guided self-organization and cortical plate formation in human brain organoids. *Nat Biotechnol* **35**, 659-666 (2017).

18. Kelava, I. & Lancaster, M.A. Stem cell models of human brain development. *Cell Stem Cell* **18**, 736-748 (2016).

19. Di Lullo, E. & Kriegstein, A.R. The use of brain organoids to investigate neural development and disease. *Nat Rev Neurosci* **18**, 573-584 (2017).

20. Heide, M., Huttner, W.B. & Mora-Bermudez, F. Brain organoids as models to study human neocortex development and evolution. *Curr Opin Cell Biol* **55**, 8-16 (2018).

21. Arlotta, P. Organoids required! A new path to understanding human brain development and disease. *Nat Methods* **15**, 27-29 (2018).

22. Pasca, S.P. *et al.* A nomenclature consensus for nervous system organoids and assembloids. *Nature* **609**, 907-910 (2022).

23. Gabriel, E. *et al.* CPAP promotes timely cilium disassembly to maintain neural progenitor pool. *EMBO J* **35**, 803-19 (2016).

24. Li, R. *et al.* Recapitulating cortical development with organoid culture in vitro and modeling abnormal spindle-like (ASPM related primary) microcephaly disease. *Protein Cell* **8**, 823-833 (2017).

25. Zhang, W. *et al.* Modeling microcephaly with cerebral organoids reveals a WDR62-CEP170-KIF2A pathway promoting cilium disassembly in neural progenitors. *Nat Commun* **10**, 2612 (2019).

26. Esk, C. *et al.* A human tissue screen identifies a regulator of ER secretion as a brain-size determinant. *Science* **370**, 935-941 (2020).

27. Iefremova, V. *et al.* An organoid-based model of cortical development identifies non-cell-autonomous defects in Wnt signaling contributing to Miller-Dieker syndrome. *Cell Rep* **19**, 50-59 (2017).

28. Bershteyn, M. *et al.* Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial glia. *Cell Stem Cell* **20**, 435-449 e4 (2017).

29. Di Donato, N. *et al.* Severe forms of Baraitser-Winter syndrome are caused by ACTB mutations rather than ACTG1 mutations. *Eur J Hum Genet* **22**, 179-83 (2014).

30. Accogli, A. *et al.* Targeted re-sequencing in malformations of cortical development: genotype-phenotype correlations. *Seizure* **80**, 145-152 (2020).

31. Eker, H.K. *et al.* Cerebro-Fronto-Facial syndrome type 3 with polymicrogyria: a clinical presentation of Baraitser-Winter syndrome. *European journal of medical genetics* (2013).

32. Rossi, M., Guerrini, R., Dobyns, W.B., Andria, G. & Winter, R.M. Characterization of brain malformations in the Baraitser-Winter syndrome and review of the literature. *Neuropediatrics* **34**, 287-92 (2003).

33. Lancaster, M.A. & Knoblich, J.A. Generation of cerebral organoids from human pluripotent stem cells. *Nat Protoc* **9**, 2329-40 (2014).

34. Huttner, W.B. & Kosodo, Y. Symmetric versus asymmetric cell division during neurogenesis in the developing vertebrate central nervous system. *Curr Opin Cell Biol* **17**, 648-57 (2005).

35. Xing, L., Wilsch-Brauninger, M. & Huttner, W.B. How neural stem cells contribute to neocortex development. *Biochem Soc Trans* **49**, 1997-2006 (2021).

36. Lancaster, M.A. & Knoblich, J.A. Spindle orientation in mammalian cerebral cortical development. *Curr Opin Neurobiol* **22**, 737-46 (2012).

37. Mora-Bermudez, F., Matsuzaki, F. & Huttner, W.B. Specific polar subpopulations of astral microtubules control spindle orientation and symmetric neural stem cell division. *Elife* **3**(2014).

38. Mora-Bermudez, F. & Huttner, W.B. Novel insights into mammalian embryonic neural stem cell division: focus on microtubules. *Mol Biol Cell* **26**, 4302-6 (2015).

39. Shitamukai, A. & Matsuzaki, F. Control of asymmetric cell division of mammalian neural progenitors. *Dev Growth Differ* **54**, 277-86 (2012).

40. Siller, K.H. & Doe, C.Q. Spindle orientation during asymmetric cell division. *Nat Cell Biol* **11**, 365-74 (2009).

41. Forth, S. & Kapoor, T.M. The mechanics of microtubule networks in cell division. *J Cell Biol* **216**, 1525-1531 (2017).

42. Di Donato, N. *et al.* Lissencephaly: Expanded imaging and clinical classification. *Am J Med Genet A* **173**, 1473-1488 (2017).

43. Quadrato, G. *et al.* Cell diversity and network dynamics in photosensitive human brain organoids. *Nature* **545**, 48-53 (2017).

44. Qian, X. *et al.* Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell* **165**, 1238-1254 (2016).

45. Ampe, C. & Van Troys, M. Mammalian actins: isoform-specific functions and diseases. *Handb Exp Pharmacol* (2016).

46. Brock, S., Cools, F. & Jansen, A.C. Neuropathology of genetically defined malformations of cortical development-A systematic literature review. *Neuropathol Appl Neurobiol* **47**, 585-602 (2021).

47. Dogterom, M. & Koenderink, G.H. Actin-microtubule crosstalk in cell biology. *Nat Rev Mol Cell Biol* **20**, 38-54 (2019).

48. König, M., Dobyns, W.B. & Di Donato, N. Lissencephaly: Update on diagnostics and clinical management. *Eur J Paediatr Neurol* **35**, 147-152 (2021).

49. Kirschner, M. & Mitchison, T. Beyond self-assembly: from microtubules to morphogenesis. *Cell* **45**, 329-42 (1986).

50. Mimori-Kiyosue, Y. & Tsukita, S. "Search-and-capture" of microtubules through plus-end-binding proteins (+TIPs). *J Biochem* **134**, 321-6 (2003).

51. Heald, R. & Khodjakov, A. Thirty years of search and capture: The complex simplicity of mitotic spindle assembly. *J Cell Biol* **211**, 1103-11 (2015).

52. Kanton, S. *et al.* Organoid single-cell genomic atlas uncovers human-specific features of brain development. *Nature* **574**, 418-422 (2019).

53. Mora-Bermudez, F. *et al.* Differences and similarities between human and chimpanzee neural progenitors during cerebral cortex development. *Elife* **5**(2016).

54. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**, 676-82 (2012).

55. Dubreuil, V., Marzesco, A.M., Corbeil, D., Huttner, W.B. & Wilsch-Bräuninger, M. Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1. *J Cell Biol* **176**, 483-95 (2007).

56. Meinhardt, A. *et al.* 3D reconstitution of the patterned neural tube from embryonic stem cells. *Stem Cell Reports* **3**, 987-99 (2014).

57. Camp, J.G. *et al.* Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. *Proc Natl Acad Sci U S A* **112**, 15672-7 (2015).

58. Mastronarde, D.N. Automated electron microscope tomography using robust prediction of specimen movements. *J Struct Biol* **152**, 36-51 (2005).

FIGURES

Fig. 1.



Fig. 1. Representative cases of malformations of cortical development in Baraitser-Winter-Cerebrofrontofacial syndrome.

(A-C) Representative MRI scans of a healthy individual at the age of 6 years.

(D-F) MRI scans of a patient with the *de novo* variant in *ACTB* NM_001101.5:c.359C>T p.Thr120Ile, at the age of 10 years. (**D**) Midline sagittal FLAIR image shows thin corpus callosum; note that the thin appearance of the brainstem most likely is a positioning artefact; (**E**) T2 weighted axial image shows thick and less folded cortex (arrows); and (**F**) coronal T1 image demonstrates bilateral periventricular nodular heterotopia (arrowheads) in the posterior horns of the lateral ventricles.

(G-I) MRI scans of a patient with the *de novo* variant in *ACTG1* NM_001614.5:c.608C>T p.Thr203Met at the age of 1 year and 8 months. **(G)** Midline sagittal T1 weighted image shows complete agenesis of the corpus callosum (arrow) and hypoplasia of the cerebellar vermis; axial **(H)** and coronal **(I)** T1 images show frontal predominant pachygyria (arrows in H).

(J-L) MRI scans of a patient with the *de novo* variant in *ACTB* NM_001101.5:c.571A>G p.Lys191Glu at the age of 1 year and 1 month. **(J)** Midline sagittal T1 weighted image shows normal brain morphology; T2 weighted axial **(K)** and T1 weighted coronal **(L)** images show frontal predominant pachygyria (arrows).

(M-O) MRI scans of a patient with the *de novo* variant in *ACTG1* NM_001614.5:c.767G>A p.Arg256Gln at the age of 1 year and 5 months (patient S12[30]). Midline sagittal T1 weighted image **(M)** shows partial agenesis of the corpus callosum (arrow); **(N)** axial image at the level of the lateral ventricles shows frontal pachygyria (arrows) and thin posterior subcortical band heterotopia (arrowheads); band heterotopia is more easily recognizable in the coronal image (arrowheads) **(O).**

Fig. 2.


A
c1 SC102A-1
c2 CRTDi011-A
ACTB
Thr120Ile
ACTG1
Thr203Met
d30
B
d50
C
Area d30
Organoid area [µm²]
8×10⁶
6×10⁶
4×10⁶
2×10⁶
0
**
****
c1 + c2
ACTB
Thr120Ile
ACTG1
Thr203Met
D
Area d50
Organoid area [µm²]
1.5×10⁷
1×10⁷
5×10⁶
0
****
****
c1 + c2
ACTB
Thr120Ile
ACTG1
Thr203Met

Fig. 2. BWCFF-S cerebral organoids show a reduction in size at 30 and 50 days of culture.

(**A,B**) Bright-field images (top rows in (**A**) and (**B**)) and DAPI-stained sections (bottom rows in (**A**) and (**B**)) of 30-days old (**A**) and 50-days old (**B**) cerebral organoids generated from two control iPSC lines (c1, SC102A-1 and c2, CRTDi011-A; left two columns), from BWCFF-S *ACTB* Thr120Ile patient-derived iPSCs (second column from right), and from BWCFF-S *ACTG1* Thr203Met patient-derived iPSCs (right column). Scale bars, 500 µm.

(**C, D**) Quantification of the organoid area in control (c1, SC102A-1 and c2, CRTDi011-A; blue bars), BWCFF-S *ACTB* Thr120Ile (red bars), and BWCFF-S *ACTG1* Thr203Met (green bars) cerebral organoid sections at culture day 30 (**C**) and day 50 (**D**). (**C**) Data are the mean of 70 control (generated from 2 different iPSC lines; indicated by circles (c1, SC102A-1) and triangles (c2, CRTDi011-A)), 34 BWCFF-S *ACTB* Thr120Ile (generated from 2 different iPSC clones; indicated by circles and triangles) and 36 BWCFF-S *ACTG1* Thr203Met (generated from 2 different iPSC clones; indicated by circles and triangles) 30 days-old cerebral organoids of 2-8 independent batches; error bars indicate SD; **, P <0.01; ****, P <0.0001 (one-way ANOVA). (**D**) Data are the mean of 56 control (generated from 2 different iPSC lines; indicated by circles and triangles as in (**C**)), 46 BWCFF-S *ACTB* Thr120Ile (generated from 2 different iPSC clones; indicated by circles and triangles) and 42 BWCFF-S *ACTG1* Thr203Met (generated from 2 different iPSC clones; indicated by circles and triangles) 50 days-old cerebral organoids of 2-8 independent batches; error bars indicate SD; ****, P <0.0001 (one-way ANOVA).

Fig. 3.



Fig. 3. BWCFF-S cerebral organoids show a reduction in VZ area and VZ progenitor number.

(**A**-**G**) All cerebral organoids are at culture day 30.

(**A**) DAPI-stained sections containing ventricle-like structures of control (c1, SC102A-1, left image), BWCFF-S *ACTB* Thr120Ile (middle image) and BWCFF-S *ACTG1* Thr203Met (right image) cerebral organoids. White lines indicate the area of the VZ; magenta lines indicate the radial thickness of the VZ at 4 different positions per ventricle-like structure. Scale bars, 50 µm.

(**B**-**D**, **F**, **G**) Quantification of various parameters of the VZ of control (c1, SC102A-1 and c2, CRTDi011-A; blue bars), BWCFF-S *ACTB* Thr120Ile (red bars) and BWCFF-S *ACTG1* Thr203Met (green bars) cerebral organoids.

(**B**) Quantification of the radial thickness of the VZ (magenta lines in (**A**)).

(**C**) Quantification of the VZ perimeter (outer white line in (**A**)).

(**D**) Quantification of the VZ area (area between the inner and outer white lines in (**A**)).

(**E**) High magnification images of DAPI-stained sections containing ventricle-like structures of control (c1, SC102A-1; left image), BWCFF-S *ACTB* Thr120Ile (middle image) and BWCFF-S *ACTG1* Thr203Met (right image) cerebral organoids. White lines indicate the borders of the VZ. Scale bars, 20 µm.

(**F**) Quantification of the cell density in a 100 μm^2 field of the VZ.

(**G**) Quantification of VZ cells per ventricle-like structure.

(**B**-**D**, **F**, **G**) Data are the mean of 35 control organoids (generated from 2 different iPSC lines; indicated by circles (c1, SC102A-1) and triangles (c2, CRTDi011-A), 159 ventricle-like structures in total), 26 BWCFF-S *ACTB* Thr120Ile organoids (generated from 2 different iPSC clones; indicated by circles and triangles, 135 ventricle-like structures in total) and 22 *ACTG1* Thr203Met organoids (generated from 2 different iPSC clones; indicated by circles and triangles, 133 ventricle-like structures in total), each from 2-3 independent batches; error bars indicate SD; ****, $P < 0.0001$ (Kruskal-Wallis test); ns, not significant (one-way ANOVA).

Fig. 4.



Fig. 4. Mitotic apical progenitors of BWCFF-S cerebral organoids predominantly show a horizontal rather than vertical cleavage plane.

(**A**) Double immunofluorescence for SOX2 (magenta) and ZO-1 (orange), combined with DAPI staining (blue), of sections of control (c2, CRTDi011-A) and BWCFF-S *ACTB* Thr120Ile 30-days old cerebral organoids, as follows. Images show representative examples of interphase (left column, c2, CRTDi011-A) and metaphase (second column from left, c2, CRTDi011-A) APs, and APs in anaphase (two right columns) with vertical (c2, CRTDi011-A; second column from right) or horizontal (*ACTB* Thr120Ile; right column) cleavage plane angle; Scale bars, 5 µm. The axis of the cleavage plane is marked with a white dotted line.

(**B**) Schematic depiction of the determination of anaphase AP cleavage plane angles relative to the apical surface (created with biorender.com). Cleavage plane angles are compiled into three groups as indicated. These three groups also apply to panels (**C**) and (**D**).

(**C, D**) Quantification (**C**) and percentage distribution (**D**) of cleavage plane angles of anaphase APs of (i) control cerebral organoids (generated from 2 different iPSC lines; indicated by circles (c1, SC102A-1) and triangles (c2, CRTDi011-A) in (**C**) and by blue bars in (**D**)); (ii) BWCFF-S *ACTB* Thr120Ile cerebral organoids (generated from 2 different iPSC clones; indicated by

circles and triangles in (**C**) and by red bars in (**D**)); and (iii) *ACTG1* Thr203Met cerebral organoids (generated from 2 different iPSC clones; indicated by circles and triangles in (**C**) and by green bars in (**D**)); all cerebral organoids are at culture day 30. Data consists of 32-86 anaphase APs, analyzed in (i) 17 control cerebral organoids (generated from 2 different iPSC lines; c1, SC102A-1: 7 cerebral organoids, 31 APs; c2, CRTDi011-A: 10 cerebral organoids, 55 APs); (ii) 15 *ACTB* Thr120Ile cerebral organoids (generated from 2 different iPSC clones; 16 APs per clone); and 17 *ACTG1* Thr203Met cerebral organoids (generated from 2 different iPSC clones; 11 and 29 APs, respectively); in each of the three conditions, the cerebral organoids are of 2 independent batches per clone. (**D**) For each of the three conditions, the numbers of mitotic AP cleavage plane angles in each group are expressed as a percentage of total (set to 100). Error bars indicate SD; **, $P < 0.01$; ****, $P < 0.0001$ (two-way ANOVA).

Fig. 5.


A
c2 CRTDi011-A
ACTB
Thr120Ile
ACTG1
Thr203Met
V
B
c1 SC102A-1
c2 CRTDi011-A
ACTB
Thr120Ile
ACTG1
Thr203Met
alpha-tubulin
beta-tubulin
alpha-tubulin beta-tubulin
SOX2
alpha-tubulin beta-tubulin

Fig. 5. BWCFF-S cerebral organoids show an increase localization of alpha- and beta-tubulin at the apical cell cortex.

(A) Transmission electron micrographs showing either longitudinal views (left and right panels) or a cross-sectional view (middle panel) of ultrathin sections containing the apical cell cortex of VZ progenitors, likely APs, of control (c2, CRTDi011-A; left panel), *ACTB* Thr120Ile (middle panel) and *ACTG1* Thr203Met (right panel) cerebral organoids. Note the higher density of microtubule bundles (black arrows) in the mutant cells. Microtubules in the mutant cells are often anchored to the adherens junction belt (white arrows) rather than being nucleated at the basal body of the primary cilium (white asterisk). Scale bars, 1 µm. V: ventricle.

(**B**) Triple immunofluorescence for alpha-tubulin (orange), beta-tubulin (green) and SOX2 (magenta) of control (c1, SC102A-1 and c2, CRTDi011-A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met (right column) 30-days old cerebral organoids. Note the strong alpha-tubulin and beta-tubulin fluorescent signal at the apical cell cortex of BWCFF-S VZ progenitors (white arrows); Scale bars, 100 µm.

Fig. 6.



Fig. 6. BWCFF-S–like *ACTB* Thr120Ile mutant cerebral organoids generated from CRISPR/Cas9-edited control CRTDi011-A iPSCs show essentially the same phenotypes as BWCFF-S *ACTB* Thr120Ile patient-derived cerebral organoids.

(**A**) Bright-field images (top rows) and DAPI-stained sections (bottom rows) of 30-days old control cerebral organoids generated from the control iPSC line CRTDi011-A (left column) or the BWCFF-S–like *ACTB* Thr120Ile mutant cerebral organoids generated from a CRISPR/Cas9-edited CRTDi011-A–derived iPSC clone (CRTDi011-A–mut*ACTB*, right column). Scale bars, 500 µm.

(**B**) Quantification of the area of 30-days old cerebral organoids generated either from the control clone CRTDi011-A (blue bar) or from the CRISPR/Cas9-edited CRTDi011-A–derived iPSC clones CRTDi011-A–mut*ACTB*-1 (circles) and CRTDi011-A–mut*ACTB*-2 (triangles), collectively referred to as cr. *ACTB* Thr120Ile organoids (red bar). Data are the mean of 53

control and 25 cr. *ACTB* Thr120Ile organoids of 1-8 independent batches; error bars indicate SD; ***, P <0.001 (unpaired Student's *t*-test).

(**C**-**F**) Quantification of various parameters of the VZ of 30 days-old control (CRTDi011-A; blue bars) and cr. *ACTB* Thr120Ile (red bars) cerebral organoids.

(**C**) Quantification of the radial thickness of the VZ.

(**D**) Quantification of the VZ perimeter.

(**E**) Quantification of the VZ area.

(**F**) Quantification of VZ cells per ventricle-like structure.

(**C-F**) Data are the mean of 19 control organoids (77 ventricle-like structures in total) and 9 cr. *ACTB* Thr120Ile organoids (symbols as in (**B**), 114 ventricle-like structures in total), each from 1-3 independent batches; error bars indicate SD; ****, P <0.0001 (unpaired Student's *t*-test (C,D,E), Mann-Whitney *U* test (F)).

Note that for the control organoids, the same data points are depicted as those indicated by triangles in Fig. 3 B-D, G (c2).

(**G,H**) Quantification (**G**) and percentage distribution (**H**) of cleavage plane angles of anaphase APs of (i) control cerebral organoids (CRTDi011-A, indicated by triangles in (**G**) and by blue bars in (**H**)); and (ii) cr. *ACTB* Thr120Ile cerebral organoids (symbols in (**G**) are as in (**B**), red bars in (**H**)); all cerebral organoids are at culture day 30. Data consists of 55 anaphase APs of 10 control cerebral organoids and 49 (circles, 21; triangles, 28) anaphase APs of 7 cr. *ACTB* Thr120Ile cerebral organoids; in each of the two conditions, the cerebral organoids are of 1-2 independent batches per clone. (**H**) For each of the two conditions, the numbers of mitotic AP cleavage plane angles in each group are expressed as a percentage of total (set to 100). Error bars indicate SD; *, P <0.05; **, P <0.01 (two-way ANOVA). Note that for the control organoids, the same data points are depicted as those indicated by triangles in panel C and by blue bars in panel D of Fig. 4 (c2).

SUPPLEMENTARY FIGURES

Suppl. Fig. 1.



Supplementary Fig. 1. Widespread distribution of βCYA and γCYA in the fetal human neocortex at 12 wpc.

(A) Double immunofluorescence for βCYA (green) and γCYA (magenta), combined with DAPI staining (blue), of a coronal 12 wpc fetal human neocortex cryosection. Representative images of the indicated 6 zones of the developing cortical wall are depicted; iSVZ, inner subventricular zone; oSVZ, outer subventricular zone; IZ, intermediate zone; CP, cortical plate; MZ, marginal zone. The right column shows a heat map of βCYA (black) and γCYA (white) immunoreactivity. Scale bar, 25 µm.

(B) Quantification of the relative fluorescence intensities for βCYA (green, upper panel) and γCYA (magenta, lower panel) across the indicated zones of the cortical wall (AJ, adherens

junction belt), using sections of paraffin-embedded 12 wpc fetal human brains from two individuals (p1, p2) and of a cryoprotected 12 wpc fetal human brain sample of one individual (c1); for p1 three sections (p1.1-p1.3), for p2 two sections (p2.1-p2.2) and for c1 one section were analyzed. The section (c1), which is shown in (**A**), is indicated in black.

(**C**) Schematic overview of a coronal 12 wpc fetal human neocortex section indicating the region (red rectangle) shown in (**A**).

Suppl. Fig. 2.



Supplementary Fig. 2. Widespread distribution of βCYA and γCYA in the developing fetal human neocortex at 16 wpc.

(**A**) Double immunofluorescence for βCYA (green) and γCYA (magenta), combined with DAPI staining (blue), of a coronal 16 wpc fetal human neocortex paraffin section. Representative images of the indicated 7 zones of the developing cortical wall are depicted; iSVZ, inner subventricular zone; oSVZ, outer subventricular zone; IZ, intermediate zone; SP, subplate; CP, cortical plate; MZ, marginal zone. The right column shows a heat map of βCYA (black) and γCYA (white) immunoreactivity. Scale bar, 25 µm. Asterisks indicate imaging artefacts.

(**B**) Quantification of the relative fluorescence intensities for βCYA (green, upper panel) and γCYA (magenta, lower panel) across the indicated zones of the cortical wall (AJ, adherens

junction belt), using sections of paraffin-embedded fetal human brains from two individuals (p1, p2); for p1 three sections (p1.1-p1.3) and for p2, one section (p2.1) were analyzed. The section (p1.2), which is shown in (**A**) is indicated in black. Note that AJ and VZ of individual p2 could not be evaluated due to the quality of the section.

(**C**) Schematic overview of a coronal 16 wpc fetal human neocortex section indicating the region (red rectangle) shown in (**A**).

Suppl. Fig. 3.



Supplementary Fig. 3. Widespread distribution of βCYA and γCYA in control and BWCFF-S cerebral organoids.

Double immunofluorescence for βCYA (green) and γCYA (magenta), combined with DAPI staining (blue), of sections of control (c1, SC102A-1 and c2, CRTDi011-A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met

(right column) 30-days old cerebral organoids showing ventricle-like structures. The bottom row shows a heat map of βCYA (black) and γCYA (white) immunoreactivity. Scale bars, 100 µm.

Suppl. Fig. 4.



Supplementary Fig. 4. Cell type composition of control and BWCFF-S cerebral organoids – analysis 1.

Triple immunofluorescence for SOX2 (magenta), nestin (orange) and CTIP2 (green), combined with DAPI staining (blue), of sections of control (c1, SC102A-1 and c2, CRTDi011-

A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met (right column) 30-days old cerebral organoids showing ventricle-like structures. Scale bars, 100 µm.

Suppl. Fig. 5.



Supplementary Fig. 5. Cell type composition of control and BWCFF-S cerebral organoids – analysis 2.

Triple immunofluorescence for SOX2 (magenta), TBR2 (orange) and Tuj1 (green), combined with DAPI staining (blue), of control (c1, SC102A-1 and c2, CRTDi011-A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met (right column) 30-days old cerebral organoids showing ventricle-like structures. Scale bars, 100 µm.

Suppl. Fig. 6.



Supplementary Fig. 6. No difference in apoptosis between control and BWCFF-S cerebral organoids.

Triple immunofluorescence for Caspase 3 (green), SOX2 (magenta) and ZO-1 (orange), combined with DAPI staining (blue), of sections of control (c1, SC102A-1 and c2, CRTDi011-A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met (right column) 30-days old cerebral organoids showing ventricle-like structures. Scale bars, 100 µm.

Suppl. Fig. 7.


A
c1 SC102A-1
c2 CRTDi011-A
ACTB
Thr120Ile
ACTG1
Thr203Met
Ki-67
SOX2 Ki-67 Pan-cadherin
B
PH3
DAPI SOX2 ZO-1 PH3
C
Cycling cells in VZ
ns
Ki-67+cells/total cells in VZ
100
80
60
40
20
0
c1 + c2
ACTB
Thr120Ile
ACTG1
Thr203Met
D
Mitotic cells in VZ
ns
PH3+cells/1 µm2 of VZ area
8×10-4
6×10-4
4×10-4
2×10-4
0
c1 + c2
ACTB
Thr120Ile
ACTG1
Thr203Met

Supplementary Fig. 7. No difference in the number of cycling VZ progenitors and mitotic APs between control and BWCFF-S cerebral organoids.

(**A**) Triple immunofluorescence for Ki-67 (orange), SOX2 (magenta) and pan-cadherin (green) of sections of control (c1, SC102A-1 and c2, CRTDi011-A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met (right column) 30-days old cerebral organoids showing ventricle-like structures. Scale bars, 100 µm.

(**B**) Triple immunofluorescence for SOX2 (magenta), phosphohistone H3 (PH3, green) and ZO-1 (orange), combined with DAPI staining (blue), of sections of control (c1, SC102A-1 and c2, CRTDi011-A; two left columns), BWCFF-S *ACTB* Thr120Ile (second column from right) and BWCFF-S *ACTG1* Thr203Met (right column) 30-days old cerebral organoids showing ventricle-like structures. Scale bars, 100 µm.

(**C**) Quantification of the proportion of DAPI$^+$ cells that are also Ki-67$^+$ in the VZ of control (c1, SC102A-1 and c2, CRTDi011-A; blue bar), BWCFF-S *ACTB* Thr120Ile (red bar) and BWCFF-S *ACTG1* Thr203Met (green bar) cerebral organoids at culture day 30. Data are the mean of 68 control (generated from 2 different iPSC lines; indicated by circles (c1, SC102A-1) and triangles (c2, CRTDi011-A)), 23 BWCFF-S *ACTB* Thr120Ile (generated from 2 different iPSC clones; indicated by circles and triangles) and 34 BWCFF-S *ACTG1* Thr203Met (generated from 2 different iPSC clones; indicated by circles and triangles) VZs of 8-12 30 days-old cerebral organoids from 1-2 independent batches; error bars indicate SD; ns, not significant (one-way ANOVA).

(**D**) Quantification of PH3$^+$cells, expressed per 1 µm^2 of the respective VZ area, of control (c1, SC102A-1 and c2, CRTDi011-A; blue bar), BWCFF-S *ACTB* Thr120Ile (red bar) and BWCFF-S *ACTG1* Thr203Met (green bar) cerebral organoids at culture day 30. Data are the mean of 59 ventricle-like structures of control organoids (generated from 2 different iPSC lines; indicated by circles (c1, SC102A-1) and triangles (c2, CRTDi011-A)), 48 ventricle-like structures of BWCFF-S *ACTB* Thr120Ile organoids (generated from 2 different iPSC clones; indicated by circles and triangles) and 37 ventricle-like structures of BWCFF-S *ACTG1* Thr203Met organoids (generated from 2 different iPSC clones; indicated by circles and

triangles), of 16-17 30 days-old cerebral organoids from 2 independent batches each; error bars indicate SD; ns, not significant (Kruskal-Wallis test).

Suppl. Fig. 8.



Supplementary Fig. 8. Morphology of apical junctional complexes in control and BWCFF-S cerebral organoids.

(A) Transmission electron micrographs of sections of control (c2, CRTDi011-A; left panel), BWCFF-S *ACTB* Thr120Ile (second panel from left) and BWCFF-S *ACTG1* Thr203Met

(generated from 2 different iPSC clones, two right panels) 30-days old cerebral organoids; longitudinal cutting plane. Each cell is connected to its neighbors by an adherens junction belt (dark line-like structures) whose arrangement is preserved in the mutant cells. Scale bar, 10 µm.

(B) High magnification transmission electron micrographs of apical adherens junction belts in control (c2, CRTDi011-A, left panel) and BWCFF-S *ACTG1* Thr203Met 30-days old cerebral organoids. Note the presence of actin bundles adjacent to the junctions both in control and *ACTG1* Thr203Met mutant APs. Scale bar, 1 µm.

(C) Transmission electron micrographs of sections of control (c2, CRTDi011-A; left panel), BWCFF-S *ACTB* Thr120Ile (generated from 2 different iPSC clones, two middle panels) and *ACTG1* Thr203Met (right panel) 30-days old cerebral organoids in cross-sectional views. Note the variable size and shape of the mutant cell circumference at the level of the adherens junction belt (dark line-like structures). Although protrusions from APs into neighboring cells exist in control organoids, they are more frequently observed in the mutant situation (white arrows). Scale bar, 10 µm. V: ventricle.

(**D**) Triple immunofluorescence for SOX2 (magenta), ZO-1 (orange) and pan-actin (green), combined with DAPI staining (blue), of sections of control (c1, SC102A-1 and c2, CRTDi011-A; two left panels) and BWCFF-S *ACTB* Thr120Ile (second panel from right) and *ACTG1* Thr203Met (right panel) 30-days old cerebral organoids; Scale bars, 100 µm.

(**E**) Exemplary images of ZO-1 immunofluorescence of sections of control (c1, SC102A-1, left panel), BWCFF-S *ACTB* Thr120Ile (middle panel) and *ACTG1* Thr203Met (right panel) 30 days-old cerebral organoids showing normal (left image) and abnormal (two right images) adherent junction belt morphology. Scale bars, 100 µm.

Supplementary Tables

Supplementary Table 1. List of antibodies.

Primary antibodies

Target	Specificity	Company	Catalog no. #	RRID	Dilution Factor
βCYA	Mouse monoclonal IgG_1 clone 4C2	bio-rad	CMCA5775GA	AB_2571580	1:50
γCYA	Mouse monoclonal IgG_{2b} clone 2A3	bio-rad	MCA5776GA	AB_2571583	1:100
alpha-tubulin	Mouse monoclonal	Sigma-Aldrich	T6199	AB_477583	1:1000
beta-tubulin	Rabbit monoclonal	abcam	ab179513		1:500
Ki-67	Rabbit polyclonal	abcam	ab15580	AB_443209	1:300
Nestin	Rabbit polyclonal	Sigma-Aldrich	N5413	AB 1841032	1:100
Pan-actin	Mouse monoclonal	Novus Biologicals	NB600-535	AB_2222881	1:200
Pan-cadherin	Mouse monoclonal	Sigma-Aldrich	C1821	AB_476826	1:300
PH3	Rat monoclonal	abcam	ab10543	AB_2295065	1:300
SOX2	Goat polyclonal	R+D Systems	AF2018	AB_355110	1:300
TBR2	Rabbit polyclonal	abcam	ab23345	AB_778267	1:300
Caspase3	Mouse monoclonal	abcam	ab208161		1:200
CTIP2	Rat monoclonal	abcam	ab18465	AB_2064130	1:300
Tuj1	Mouse monoclonal	BioLegend	801201	AB_2313773	1:200
ZO-1	Rabbit polyclonal	Invitrogen	61-7300	AB_138452	1:300
DAPI		Roche	10236276001		1:1000

Secondary antibodies

Host/Target	Isotype	Conjugate	Company	Catalog no. #	RRID	Dilution Factor
Goat anti Mouse	Mouse IgG, Fcγ Subclass 1 Specific	AlexaFluor 488	Jackson Immunoresearch	115-545-205	AB_2338854	1:200
Goat anti Mouse	Mouse IgG, Fcγ Subclass 2b Specific	CY5	Jackson Immunoresearch	115-175-207	AB_2338717	1:50
Donkey anti Mouse	Donkey IgG	AlexaFluor 488	Thermo Fisher	A-21202	AB_141607	1:500

Donkey anti Rabbit	Donkey IgG	AlexaFluor 555	Thermo Fisher	A-31572	AB_162543	1:500
Donkey anti Goat	Donkey IgG	AlexaFluor 647	Thermo Fisher	A-21447	AB_2535864	1:500
Donkey anti Rat	Donkey IgG	AlexaFluor 488	Thermo Fisher	A-21208	AB_2535794	1:500